NDA 204508 · Baxter Hlthcare Corp
Clinolipid 20%
Olive Oil, Soybean Oil · Intravenous · Lipid Emulsion
Priority reviewLast checked: Nov 20, 2026Latest source record: Jul 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Oct 3, 2013
Approved uses
2
Original approval plus efficacy supplements
Registered trials
133
36 Phase 3, 6 recruiting
FAERS reports
32
15 serious, 5 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 24, 2025.
CLINOLIPID is indicated in adults and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated. CLINOLIPID is indicated in adults and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated. ( 1 )
Mechanism: Fatty acids serve as an important substrate for energy production. The most common mechanism of action for energy production derived from fatty acid metabolism is beta oxidation. Fatty acids are important for membrane structure and function, precursors for bioactive molecules (such as prostaglandins), and as regulators of gene expression.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 24, 2024 Supplement 22 · Efficacy LetterLabel
- Oct 3, 2013 Original approval · Type 5 - New Formulation or New Manufacturer · priority review ReviewSummary ReviewLabel
1 products under this application
- CLINOLIPID 20% · OLIVE OIL 16%(160GM/1000ML); SOYBEAN OIL 4% (40GM/1000ML) · EMULSION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Olive Oil" as an intervention, any sponsor and status, largest first.
- The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00069784 · 12,537 participants · Start Aug 2003 · Primary completion Dec 2011
Drug: insulin glargine (HOE901); omega-3 polyunsaturated fatty acids (PUFA) and 1 more · For: Diabetes Mellitus, Non-Insulin-Dependent
Sites: Bridgewater, New Jersey; Buenos Aires, Argentina; Cove, Australia · 40 sites in all
- Risk and Prevention Study: Evaluation of the Efficacy of n-3 PUFA in Subjects at High Cardiovascular RiskPivotal-lookingCompleted
Mario Negri Institute for Pharmacological ResearchAcademic, hospital or other
NCT00317707 · 12,513 participants · Start Feb 2004 · Primary completion Oct 2011
Drug: N-3 Polyunsaturated Fatty Acids; Placebo: Olive oil · For: Cardiovascular Diseases
Sites: Milan, Italy
- OMEGA-Study: Effect of Omega 3-Fatty Acids on the Reduction of Sudden Cardiac Death After Myocardial InfarctionPivotal-lookingCompleted
Stiftung Institut fuer HerzinfarktforschungAcademic, hospital or other
NCT00251134 · 3,800 participants · Start Oct 2003 · Primary completion Jun 2008
Drug: Zodin (drug); Olive oil (placebo) · For: Myocardial Infarction
Sites: Ludwigshafen am Rhein, Germany; Duisburg, Germany; Essen, Germany · 10 sites in all
- Kabul Vitamin D Supplementation TrialPivotal-lookingStatus unknown
London School of Hygiene and Tropical MedicineAcademic, hospital or other
NCT00548379 · 3,048 participants · Start Nov 2007 · Primary completion Jun 2009
Drug: vitamin D; placebo · For: Pneumonia; Vitamin D Deficiency
Sites: Kabul, Afghanistan · 2 sites in all
- Omega-3 Fatty Acids for Prevention of Post-Operative Atrial FibrillationPivotal-lookingCompleted
Brigham and Women's HospitalAcademic, hospital or other
NCT00970489 · 1,516 participants · Start Aug 2010 · Primary completion May 2012
Drug: Omega -3 fatty acids; Placebo · For: Atrial Fibrillation
Sites: Boston, Massachusetts
- [E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROLPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT01408303 · 646 participants · Start Aug 2011 · Primary completion Jun 2012
Drug: Olive oil, 4g; omega-3-carboxylic acids, 2g and 1 more · For: Hypertriglyceridemia; Cardiovascular Disease
Sites: Muscle Shoals, Alabama; Chandler, Arizona; Phoenix, Arizona · 89 sites in all
- Dry Eye Assessment and Management StudyPivotal-lookingCompleted
University of PennsylvaniaAcademic, hospital or other
NCT02128763 · 535 participants · Start Nov 2014 · Primary completion Sep 5, 2017
Drug: Omega-3 supplements; Placebo · For: Dry Eye
Sites: Scottsdale, Arizona; Azusa, California; Berkeley, California · 27 sites in all
- Olive Oil's Cream Effectiveness in Prevention of Pressure Ulcers in Immobilized Patients in Primary CarePivotal-lookingStatus unknown
Andaluz Health ServiceGovernment (non-federal)
NCT01595347 · 410 participants · Start Jan 2012 · Primary completion Sep 2013
Drug: Hyper-oxigenated fatty acid · For: Pressure Ulcer
Sites: Málaga, Spain
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- liver function test increased5
- flushing4
- nausea4
- blood alkaline phosphatase increased3
- drug ineffective3
- pruritus3
- urticaria3
- alanine aminotransferase increased2
- aspartate aminotransferase increased2
- back pain2
- blood triglycerides increased2
- death2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 4 |
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 7 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 5 |
| 2026 | 4 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The role of the Mediterranean diet in reducing the risk of cognitive impairement, dementia, and Alzheimer's disease: a meta-analysis.
Fekete M, Varga P, Ungvari Z, et al. · Geroscience 2025 · Meta-Analysis, Systematic Review
- Comparison of canola oil and olive oil consumption on the serum lipid profile in adults: a systematic review and meta-analysis of randomized controlled trials.
Pourrajab B, Sharifi-Zahabi E, Soltani S, et al. · Crit Rev Food Sci Nutr 2023 · Meta-Analysis, Systematic Review
- Effect of olive oil consumption on cardiovascular disease, cancer, type 2 diabetes, and all-cause mortality: A systematic review and meta-analysis.
Martínez-González MA, Sayón-Orea C, Bullón-Vela V, et al. · Clin Nutr 2022 · Meta-Analysis, Systematic Review
- The effects of Canola oil on cardiovascular risk factors: A systematic review and meta-analysis with dose-response analysis of controlled clinical trials.
Amiri M, Raeisi-Dehkordi H, Sarrafzadegan N, et al. · Nutr Metab Cardiovasc Dis 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Olive oil and body fat: a systematic review with meta-analysis.
Santos ACNA, Duarte de Souza ML, Machado AM, et al. · Food Funct 2023 · Meta-Analysis, Systematic Review
- Efficacy and safety of dietary polyphenols in rheumatoid arthritis: A systematic review and meta-analysis of 47 randomized controlled trials.
Long Z, Xiang W, He Q, et al. · Front Immunol 2023 · Meta-Analysis, Systematic Review
Sponsor: Baxter Hlthcare Corp
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.